This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
CRD summary
The study compared costs and consequences of acellular dermal matrices in breast reconstructive surgery. The author concluded that fetal bovine acellular matrices (SurgiMend) was preferable to human cadaveric acellular matrices (AlloDerm) due to its complication profile, price, sterility and handling characteristics. The study was transparently reported but excluded potentially relevant interventions and had potential for bias due to study design. The study should not be used to draw firm conclusions about the cost-effectiveness of SurgiMend compared to AlloDerm.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The study compared costs and complications of acellular dermal matrices in breast reconstructive surgery.
Interventions
Fetal bovine acellular dermal matrices (SurgiMend) were compared to human cadaveric acellular dermal matrices (AlloDerm) in breast reconstructive surgery after mastectomy. Patients had immediate implant-based breast reconstruction surgery by a one-stage process where the breast implant was inserted immediately or a two-stage process where a tissue expander was used before insertion of a permanent breast implant.
Location/setting
USA/Secondary Care
Methods

Analytical approach:
The cost-effectiveness analysis was based on a retrospective cohort study of 281 patients (440 breast reconstruction) with surgeries performed by a single surgeon between 2005 and 2010. The study had variable follow-up depending on whether patients had a one-stage or two-stage procedure. The study perspective was not stated explicitly.
Effectiveness data:
The primary measure of effectiveness was complications experienced by patients post surgery. Complications were monitored for the period between exchange of tissue expanders and permanent implants for two-stage procedures or for a minimum of three months from implant placement for one-stage procedures. Complications included infection, seroma, haematoma, major necrosis (requiring excision in the operating room), minor necrosis (addressed in office) and breast implant removal.
Patients were compared at baseline for demographic differences including age, body mass index, pre-operative bra size and medical risk factors (such as diabetes, hypertension, coronary arterial disease, smoking, chemotherapy and radiation therapy). There were 222 SurgiMend patients (351 breast reconstructions) and 59 AlloDerm patients (89 breast reconstructions).
Monetary benefit and utility valuations:
Not relevant.
